|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||35.79 - 36.29|
|52 Week Range||29.83 - 36.60|
|PE Ratio (TTM)||26.21|
|Forward Dividend & Yield||1.28 (3.52%)|
|1y Target Est||N/A|
The London-listed consumer group is doing what activist Nelson Peltz wants Procter & Gamble to do—but M&A may be an ulterior motive.
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
On Oct. 18, the Dow Jones Industrial Average hit a new all-time intraday high of 23,145 as of this writing. Investors who aren’t playing the indices can gain exposure to the Dow Jones today through the SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA). With the index up 16.3% in 2017, though, how much longer can this rally continue?
Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. It hopes to improve performance in its newly expanded health business, while bringing greater focus and accountability to its slower-growth home and hygiene business. Reckitt, whose products range from Durex condoms to Lysol disinfectant, has blamed fallout from a cyber attack, a failed product launch and a safety scandal in South Korea for its lacklustre sales.
In the physics of business, the entropic forces that break down a system can also liberate energy. Hidden value is meant to be released from spin-offs and the like, especially when profit growth slows. ...
Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. The change follows ...
Reckitt Benckiser (RB.L) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The maker of Durex condoms, Nurofen tablets and Dettol cleaners announced the restructuring on Wednesday, along with its third-quarter sales figures. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales.
Reckitt Benckiser Group Plc separated its home-care and health businesses, sharpening its focus on brands such as Durex condoms and Enfamil baby formula after a second cut in the sales forecast this year....
Results of a 32-patient study of a drug made by Ignyta Pharmaceuticals, a San Diego-based drugmaker, are a best case scenario for the company. The drug shrank tumors in 79% of patients and kept workingabout 10 months longer than the current drug, Pfizer’s Xalkori, did in earlier clinical trials.
Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.
The quest for the “holy grail” of cardiovascular therapy - a drug that dramatically lowered LDL-c and raised HDL-c and which would hopefully reverse atherosclerosis - has ended ignominiously.
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
Customers may be starting to shop for over-the-counter drugs in the same way they shop for groceries—with a keener eye for cost and content—and this could be painful for consumer-health companies.
A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 ...